Key features and details
- HRP Rabbit monoclonal [EPR1108] to Interferon gamma
- Suitable for: WB, IHC-P
- Reacts with: Human
- Conjugation: HRP
Product nameHRP Anti-Interferon gamma antibody [EPR1108]
See all Interferon gamma primary antibodies
DescriptionHRP Rabbit monoclonal [EPR1108] to Interferon gamma
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide within Human Interferon gamma aa 1-100 (internal sequence). The exact sequence is proprietary.
- WB: MOLT4, Jurkat whole cell lysates. IHC-P: Human lymph node (Hodgkin's lymphoma).
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Anti-Interferon gamma antibody [EPR1108] (ab133566)
- Anti-Caveolin-3 antibody [EPR11082] (ab173575)
- Anti-Interferon gamma antibody [EPR1108] - BSA and Azide free (ab185900)
- Anti-Interferon gamma antibody [EPR1108] - Low endotoxin, Azide free (ab246686)
- Anti-Caveolin-3 antibody [EPR11082] - BSA and Azide free (ab249773)
Our Abpromise guarantee covers the use of ab194149 in the following tested applications.
|WB||1/5000. Detects a band of approximately 26 kDa (predicted molecular weight: 19 kDa).|
FunctionProduced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Tissue specificityReleased primarily from activated T lymphocytes.
Involvement in diseaseIn Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
Sequence similaritiesBelongs to the type II (or gamma) interferon family.
modificationsProteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
- Information by UniProt
- IF 1 antibody
- IFG antibody
- IFI antibody
IHC image of Interferon gamma staining in a section of formalin-fixed paraffin-embedded human lymph node (Hodgkin's lymphoma)*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab194149, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
All lanes : HRP Anti-Interferon gamma antibody [EPR1108] (ab194149) at 1/5000 dilution
Lane 1 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate
Lane 2 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 19 kDa
Observed band size: 26 kDa why is the actual band size different from the predicted?
Exposure time: 20 minutes
This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab194149 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab194149 has not yet been referenced specifically in any publications.